INFO & CONTACTS:  +39 02 2390 1

A Phase II/III, multisite, randomized master protocol for a global trial of BNT327 in combination with chemotherapy and other investigational agents in first-line non-small cell lung cancer

Phase: Phase II-III clinical trials

Principal Investigator: Dott.ssa Beninato Teresa

Main Facility: Oncologia Medica Toraco-Polmonare

Drug: BNT327

Pathologies: Lung cancer

A Phase II/III, multisite, randomized master protocol trial on the efficacy, tolerability, and safety of BNT327 in combination with chemotherapy compared to pembrolizumab plus chemotherapy in patients with first-line non-small cell lung cancer (NSCLC). The trial is divided into two parts: 

Phase II Part: A randomized trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and efficacy of two different dose levels of BNT327 (20 mg/kg versus 30 mg/kg every 3 weeks) in combination with chemotherapy.

Phase III Part: A global, randomized trial to compare the efficacy and safety of BNT327 in combination with chemotherapy (Experimental Arm) versus pembrolizumab plus chemotherapy (Standard of Care Control Arm), with enrollment expanded to 1220 participants.

Last update: 13/07/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe